Dholera Special Investment Region (SIR) is emerging as a major pharmaceutical and biotechnology manufacturing hub in India. With world-class infrastructure, strategic location, and strong government incentives, Dholera is attracting significant interest from pharma giants, biotech companies, and healthcare R&D firms.

The Indian government’s Make in India and Atmanirbhar Bharat initiatives are driving investments in Active Pharmaceutical Ingredients (APIs), vaccine manufacturing, and contract drug development in Dholera. This will help India become self-reliant in medicine production, reduce dependence on imports, and increase pharma exports to global markets.

Why Dholera SIR is the Best Location for the Pharmaceutical Industry?

Dholera SIR provides several advantages that make it an ideal destination for pharmaceutical companies:

Smart Industrial Infrastructure: Dholera is being developed as India’s first greenfield smart city, featuring AI-powered logistics, advanced connectivity, and modern industrial zones. The plug-and-play infrastructure ensures that pharma companies can set up production and R&D facilities quickly and efficiently.

Proximity to Ports & Airports: Dholera’s location near major ports and the upcoming international airport makes it easy for pharma companies to export medicines, vaccines, and biotech products worldwide. This reduces logistics costs and speeds up global distribution.

Cost-Effective Manufacturing: The availability of affordable industrial land and lower operational costs makes Dholera an attractive option for bulk drug manufacturing, biotech production, and pharmaceutical R&D centers.

Government Support & Incentives: The government is offering tax benefits, land subsidies, and single-window clearance to attract pharmaceutical companies to Dholera. These incentives reduce setup costs and improve ease of doing business for investors.

Strong Research & Innovation Ecosystem: With planned biotech parks, pharma R&D hubs, and collaborations with research institutions, Dholera is expected to become a leading innovation center for drug discovery, vaccine research, and biotechnology advancements.

Key Segments of the Pharmaceutical Industry in Dholera

1. Active Pharmaceutical Ingredient (API) Manufacturing

• India currently imports a large percentage of APIs from China. To reduce dependency, the government is encouraging API production in Dholera SIR.
• Potential Investors: Several pharmaceutical companies are exploring investment opportunities.
• Key Benefits: Cost-effective production, government subsidies, export opportunities.

2. Generic Drug Manufacturing

• India is the largest exporter of generic medicines, and Dholera will play a significant role in increasing production.
• Potential Investors: Domestic and global pharma firms looking to expand in India.
• Key Focus Areas: Affordable medicines, over-the-counter (OTC) drugs, and international pharma exports.

3. Vaccine & Biopharmaceuticals Manufacturing

• With India’s leading global vaccine production, Dholera will host cutting-edge biotech and vaccine plants.
• Potential Investors: Biotech firms and government-backed initiatives.
• Key Focus Areas: Vaccine development, biosimilars, biotech innovation.

4. Contract Development & Manufacturing (CDMO)

• Many international pharma companies prefer India for contract drug manufacturing. Dholera offers an ideal setup for these operations.
• Potential Investors: Indian and global CDMO firms.
• Key Focus Areas: Third-party drug production, formulation research, and clinical trials.

5. Herbal & Ayurvedic Medicine Manufacturing

• The demand for Ayurveda-based and organic medicines is growing globally.
• Potential Investors: Ayurvedic medicine manufacturers and wellness brands.
• Key Focus Areas: Herbal medicines, Ayurvedic healthcare, nutraceuticals.

Potential Pharmaceutical Investments in Dholera

Gujarat is already a major hub for the pharmaceutical industry, home to renowned companies such as Zydus Lifesciences, Cadila Pharmaceuticals, Sun Pharma, Torrent Pharmaceuticals, and Intas Pharmaceuticals. These industry leaders have established Gujarat as a powerhouse for pharma manufacturing, research, and exports.

With Dholera emerging as a key industrial and smart city, its pharmaceutical sector stands to benefit immensely from Gujarat’s existing ecosystem. The presence of established pharma giants ensures access to skilled manpower, raw materials, regulatory expertise, and a strong supply chain. Dholera’s world-class infrastructure, strategic location, and ease of doing business make it a prime destination for new pharma investments, reinforcing Gujarat’s leadership in the sector.

While several companies have expressed interest in setting up pharmaceutical plants in Dholera SIR, no official MoUs or announcements have been made yet. However, discussions are ongoing, and the region is expected to attract major pharma players as infrastructure development progresses.

Conclusion: Dholera – India’s Next Pharma & Biotech Powerhouse

Dholera SIR is on track to become a global leader in pharmaceutical and biotechnology manufacturing. The region’s modern infrastructure, strategic location, and government-backed incentives are attracting major pharma investments, making it a key player in India’s healthcare and pharmaceutical future.

Looking for Investment Opportunities in Dholera’s Pharma Sector?

If you are considering pharmaceutical or biotech investments, now is the time! Contact us today to explore industrial and real estate opportunities in Dholera SIR.